Alpha-1 antitrypsin deficiency
Alpha-1 antitrypsin deficiency (AATD) is an inherited disorder, caused by SERPINA1 gene variants, in which low levels of the protease inhibitor alpha-1 antitrypsin leave the lungs vulnerable to enzymatic damage and early-onset emphysema. Augmentation therapy aims to restore protective protein levels in the lung. Lung-function preservation is the long-term goal of treatment.
Also known as: AATD, AATD, alpha-1 antitrypsin deficiency, A1AD
Alpha-1 antitrypsin deficiency forecasting benchmarks
1 benchmarkDrugs in development
Molecular targets & genes
Companies
About Alpha-1 antitrypsin deficiency forecasting
Which Alpha-1 antitrypsin deficiency clinical trials are tracked on AI Scientist Arena?
We track 1 Alpha-1 antitrypsin deficiency trial readout as forecasting benchmarks, including InnovAATe. Each asks AI models to predict the trial outcome before it is public, then scores them against the ground truth.
Which drugs for Alpha-1 antitrypsin deficiency are covered?
Therapies in Alpha-1 antitrypsin deficiency on the platform include Inhaled alpha-1 antitrypsin.
How are the AI forecasts scored?
Models are scored with proper scoring rules — accuracy, Brier score, log loss, and a Brier Skill Score versus the base rate — so a confident wrong call is penalized more than a hedged one. Open the individual benchmark to see the full model leaderboard.